A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas (Q44361615)
Jump to navigation
Jump to search
scientific article published on 3 January 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas |
scientific article published on 3 January 2012 |
Statements
1 reference
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas (English)
1 reference
Sagar Lonial
1 reference
Rajni Sinha
1 reference
Jonathan L Kaufman
1 reference
Hanna Jean Khoury
1 reference
Nassoma King
1 reference
Pareen J Shenoy
1 reference
Carol Lewis
1 reference
Kevin Bumpers
1 reference
Amanda Hutchison-Rzepka
1 reference
Mourad Tighiouart
1 reference
Leonard T Heffner
1 reference
Mary Jo Lechowicz
1 reference
Christopher R Flowers
1 reference
3 January 2012
1 reference
1 reference
118
1 reference
14
1 reference
3538-3548
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference